Correvio Pharma Corp. (NASDAQ:CORV) is reporting first quarter earnings results on Monday 29th June 2020, .
The consensus estimates from Thomson Reuters are $ 9.50 million in revenue.
For the full year, analysts predict revenues of $ 49.53 million, while looking forward to loss of $ 0.31 per share.
Historical Earnings Performance
The pervious quarter 4Q19 results beat wall street view, the report interpreted loss of $ 0.07 per share from the top line of $ 11.33 million, analysts anticipated loss of $ 0.12 per share
wpDataChart with provided ID not found! wpDataTable with provided ID not found!
Stock Performance
According to the previous trading day, closing price of CORV was $ 0.42, representing a 100.00 % increase from the 52 week low of $ 0.21 and a 84.95 % decrease over the 52 week high of $ 2.79.
The company has a market capital of $ 27.79 million and is part of the Healthcare sector and Drug Manufacturers – Specialty & Generic industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”CORV” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Correvio Pharma Corp., a specialty pharmaceutical company, engages in developing therapeutics worldwide. Its portfolio of marketed brands comprise Aggrastat (tirofiban hydrochloride) for patients with acute coronary syndrome; and Brinavess (vernakalant IV) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm. The company also offers ESMOCARD and ESMOCARD LYO, a short acting beta blocker for the treatment of supraventricular tachycardia and control of the ventricular rate in patients with atrial fibrillation; Trevyent, a development stage drug/device combination product for pulmonary arterial hypertension; Xydalba, a treatment for acute bacterial skin and skin structure infections; and Zevtera/Mabelio, a cephalosporin antibiotic for intravenous administration with rapid bactericidal activity.
